Kynurenine pathway dysregulation as a mechanistic link between cognitive impairment and brain damage: Implications for multiple sclerosis

被引:0
作者
Kupjetz, Marie [1 ]
Chirino, Tiffany Y. Wences [1 ]
Joisten, Niklas [1 ,2 ]
Zimmer, Philipp [1 ]
机构
[1] TU Dortmund Univ, Inst Sport & Sport Sci, Res Grp Sports Med, Otto Hahn Str 3, D-44227 Dortmund, Germany
[2] Univ Gottingen, Inst Sport Sci, Div Exercise & Movement Sci, Sprangerweg 2, D-37075 Gottingen, Germany
关键词
Multiple sclerosis; Tryptophan; Kynurenine; Central nervous system; Inflammation; Cognition; EXTRACELLULAR DOPAMINE LEVELS; MAJOR DEPRESSIVE DISORDER; WHITE-MATTER INTEGRITY; NEURONAL CELL-DEATH; QUINOLINIC ACID; INDOLEAMINE 2,3-DIOXYGENASE; 3-HYDROXYANTHRANILIC ACID; TRYPTOPHAN CATABOLITE; PROCESSING SPEED; PICOLINIC-ACID;
D O I
10.1016/j.brainres.2024.149415
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cognitive impairment is a core symptom of multiple sclerosis (MS), resulting from inflammation-related brain damage and brain network dysfunction. Inflammation also causes dysregulation of the kynurenine pathway, which is the primary route of tryptophan metabolism. Kynurenine pathway dysregulation is characterised by a shift in concentrations of tryptophan catabolites, also referred to as kynurenines. Some kynurenines have neurotoxic effects that partly resemble the molecular mechanisms of MS pathophysiology underpinning brain damage and brain network dysfunction. The kynurenine pathway may therefore qualify as a mechanistic link between systemic inflammation, brain damage, and cognitive impairment in MS. This perspective article (1) provides an overview of inflammation-related kynurenine pathway dysregulation and MS-relevant neuroimmune properties of kynurenines and (2) summarises the current evidence on associations between systemic kynurenines, imaging metrics of brain structure or related markers, and cognitive performance in populations that present with kynurenine pathway dysregulation and are prone to cognitive impairment. These findings are used to (3) set a research agenda for future studies aimed at clarifying the role of the kynurenine pathway in brain damage and cognitive impairment in MS.
引用
收藏
页数:20
相关论文
共 208 条
  • [1] Blood GFAP as an emerging biomarker in brain and spinal cord disorders
    Abdelhak, Ahmed
    Foschi, Matteo
    Abu-Rumeileh, Samir
    Yue, John K.
    D'Anna, Lucio
    Huss, Andre
    Oeckl, Patrick
    Ludolph, Albert C.
    Kuhle, Jens
    Petzold, Axel
    Manley, Geoffrey T.
    Green, Ari J.
    Otto, Markus
    Tumani, Hayrettin
    [J]. NATURE REVIEWS NEUROLOGY, 2022, 18 (03) : 158 - 172
  • [2] Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate
    Aharoni, Rina
    Schottlender, Nofar
    Bar-Lev, Dekel D.
    Eilam, Raya
    Sela, Michael
    Tsoory, Michael
    Arnon, Ruth
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [3] Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: Facts and challenges
    Albuquerque, Edson X.
    Schwarcz, Robert
    [J]. BIOCHEMICAL PHARMACOLOGY, 2013, 85 (08) : 1027 - 1032
  • [4] Acute elevations of brain kynurenic acid impair cognitive flexibility: Normalization by the alpha7 positive modulator galantamine
    Kathleen S. Alexander
    Hui-Qiu Wu
    Robert Schwarcz
    John P. Bruno
    [J]. Psychopharmacology, 2012, 220 (3) : 627 - 637
  • [5] SPECIFIC INHIBITION OF KYNURENATE SYNTHESIS ENHANCES EXTRACELLULAR DOPAMINE LEVELS IN THE RODENT STRIATUM
    Amori, L.
    Wu, H. -Q.
    Marinozzi, M.
    Pellicciari, R.
    Guidetti, P.
    Schwarcz, R.
    [J]. NEUROSCIENCE, 2009, 159 (01) : 196 - 203
  • [6] Badawy AAB, 2017, INT J TRYPTOPHAN RES, V10, DOI 10.1177/1178646917691938
  • [7] Relation of the kynurenine pathway with normal age: A systematic review
    Bakker, Lieke
    Choe, Kyonghwan
    Eussen, Simone J. P. M.
    Ramakers, Inez H. G. B.
    van den Hove, Daniel L. A.
    Kenis, Gunter
    Rutten, Bart P. F.
    Verhey, Frans R. J.
    Koehler, Sebastian
    [J]. MECHANISMS OF AGEING AND DEVELOPMENT, 2024, 217
  • [8] Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder
    Bakkour, Nadia
    Samp, Jennifer
    Akhras, Kasem
    El Hammi, Emna
    Soussi, Imen
    Zahra, Fatma
    Duru, Gerard
    Kooli, Amna
    Toumi, Mondher
    [J]. PSYCHIATRY RESEARCH, 2014, 216 (03) : 291 - 302
  • [9] Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients
    Barro, Christian
    Healy, Brian C.
    Saxena, Shrishti
    Glanz, Bonnie, I
    Paul, Anu
    Polgar-Turcsanyi, Mariann
    Guttmann, Charles R. G.
    Bakshi, Rohit
    Weiner, Howard L.
    Chitnis, Tanuja
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (02) : 206 - 211
  • [10] Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis
    Batista, Sonia
    Zivadinov, Robert
    Hoogs, Marietta
    Bergsland, Niels
    Heininen-Brown, Mari
    Dwyer, Michael G.
    Weinstock-Guttman, Bianca
    Benedict, Ralph H. B.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 (01) : 139 - 146